rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Mohammad Azab

Director

Company insider

Files Form 4 as: Director, Lisata Therapeutics; Director, Durect; Director, Xenon Pharmaceuticals; Chief Medical Officer, Astex Pharmaceuticals.

Every Form 4 they filed

In numbers

Trades disclosed
76
Buys
8
Sells
1
Bought
$105K
Sold
$214
Companies
4
Companies where not an officer
3
First trade
21 Jul 2009
Last trade
9 Jan 2026
Last filed
13 Jan 2026

Companies traded

Where they are an officer
Astex PharmaceuticalsOfficer · last 11 Oct 20130 buys · 0 sells
Everywhere else they filed: board seats, 10% stakes, other companies
LSTA Lisata TherapeuticsDirector · Biotechnology · last 9 Jan 20260 buys · 0 sells
DurectDirector · last 11 Sep 20253 buys · 0 sells
XENE Xenon PharmaceuticalsDirector · Biotechnology · last 19 Dec 20235 buys · 1 sell

Activity over time

1 Nov 2024 – 1 Oct 2026
101Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
9 Jan 2026filed 13 Jan 2026LSTA Lisata TherapeuticsBiotechnologySEC FORM 4 Code A—30,456 at $0.00filing
9 Jan 2026filed 13 Jan 2026LSTA Lisata TherapeuticsBiotechnologySEC FORM 4 Code A—30,456 at $0.00filing
11 Sep 2025filed 12 Sep 2025Durectoption or derivativeSEC FORM 4 Code D—7,000filing
11 Sep 2025filed 12 Sep 2025Durectoption or derivativeSEC FORM 4 Code D—2,750filing
11 Sep 2025filed 12 Sep 2025Durectoption or derivativeSEC FORM 4 Code D—5,500filing
11 Sep 2025filed 12 Sep 2025Durectoption or derivativeSEC FORM 4 Code D—5,500filing
11 Sep 2025filed 12 Sep 2025Durectoption or derivativeSEC FORM 4 Code D—5,500filing
11 Sep 2025filed 12 Sep 2025DurectSEC FORM 4 Code U—6,000filing
9 Jan 2025filed 13 Jan 2025LSTA Lisata TherapeuticsBiotechnologySEC FORM 4 Code A—15,789 at $0.00filing
25 Sep 2024filed 27 Sep 2024Durectoption or derivativeSEC FORM 4 Code A—5,500 at $0.00filing
9 Jan 2024filed 11 Jan 2024LSTA Lisata TherapeuticsBiotechnologySEC FORM 4 Code A—19,480 at $0.00filing
19 Dec 2023filed 20 Dec 2023XENE Xenon Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code M—823 at $0.00filing
19 Dec 2023filed 20 Dec 2023XENE Xenon Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code M—3,497 at $0.00filing
19 Dec 2023filed 20 Dec 2023XENE Xenon PharmaceuticalsBiotechnologySEC FORM 4 Code M$8,107823 at $9.85filing
19 Dec 2023filed 20 Dec 2023XENE Xenon PharmaceuticalsBiotechnologySEC FORM 4 Code M$34K3,497 at $9.85filing
21 Jun 2023filed 23 Jun 2023Durectoption or derivativeSEC FORM 4 Code A—5,500 at $0.00filing
2 Jun 2023filed 2 Jun 2023XENE Xenon Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code A—18,475 at $0.00filing
9 Jan 2023filed 11 Jan 2023LSTA Lisata TherapeuticsBiotechnologySEC FORM 4 Code A—20,000 at $0.00filing
12 Dec 2022filed 13 Dec 2022XENE Xenon Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code M—3,086 at $0.00filing
12 Dec 2022filed 13 Dec 2022XENE Xenon PharmaceuticalsBiotechnologySEC FORM 4 Code M$8,2703,086 at $2.68filing

Sectors

Health Care6
Not placed3

Buys in green, sells in red, by the company’s sector.

Related people

Ian MortimerPresident & CEO · Also traded XENE in the last 90 days
Thomas Patrick KellyChief Financial Officer · Also traded XENE in the last 90 days
Christopher John KenneyChief Medical Officer · Also traded XENE in the last 90 days
Steven GannonDirector · Also traded XENE in the last 90 days